CITED2 mutation and methylation in children with congenital heart disease.
BACKGROUND
The occurrence of Congenital Heart Disease (CHD) is resulted from either genetic or environmental factors or the both. The CITED2 gene deletion or mutation is associated with the development of cardiac malformations. In this study, we have investigated the role of CITED2 gene mutation and methylation in the development of Congenital Heart Disease in pediatric patients in China.


RESULTS
We have screened 120 pediatric patients with congenital heart disease. Among these patients, 4 cases were detected to carry various CITED2 gene heterozygous mutations (c.550G > A, c.574A > G, c.573-578del6) leading correspondingly to the alterations of amino acid sequences in Gly184Ser, Ser192Gly, and Ser192fs, respectively. No CITED2 gene mutations were detected in the control group. At the same time, we found that CITED2 mutations could inhibit TFAP2c expression. In addition, we have demonstrated that abnormal CITED2 gene methylation was detected in most of the tested pediatric patients with CHD, which leads to a decrease of CITED2 transcription activities.


CONCLUSIONS
Our study suggests that CITED2 gene mutations and methylation may play an important role in the development of pediatric congenital heart disease.
Min
M
Xu
Department of Cardiology, Children's Hospital of Chongqing Medical University, 136 Zhongshan Er Road, Chongqing 400014, P,R, China. chongwxy@aliyun.com.
Xiaoyun
X
Wu
Yonggang
Y
Li
Xiaofei
X
Yang
Jihua
J
Hu
Min
M
Zheng
Jie
J
Tian
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D019175:DNA Methylation / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D006330:Heart Defects, Congenital / Q000235:genetics* / Q000503:physiopathology; D006801:Humans; D007223:Infant; D008297:Male; D009154:Mutation; D012097:Repressor Proteins / Q000235:genetics*; D015534:Trans-Activators / Q000235:genetics*
C486381:CITED2 protein, human; D004268:DNA-Binding Proteins; D012097:Repressor Proteins; D015534:Trans-Activators